Disc Medicine
IRON
61.18
-0.47
-0.76%
Disc Medicine
US · IRON
#2647 by market cap
Listed 1970
61.18
-0.47
-0.76%
Live - 5344 symbols - heartbeat 546s ago
· 2026-10-08 07:13
Pre-market
60.70
-0.78%
After-hours
61.12
-0.10%
- Market cap
- 2.35B
- P/E (TTM)i
- -9.28
- P/Bi
- 3.65
- EPSi
- -6.01
- Div yieldi
- 0.00%
- 52W posi
- 36%
Reader sentiment
Are you bullish or bearish on IRON?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.4 percentage points.
Institutional ownership
- Held by institutions
- 121.04% -0.43pp
- Institutions
- 269 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund60.80%
VC/PE Fund30.09%
Hedge Fund24.96%
Private Company3.04%
Public Company1.40%
Individual/Insider0.57%
Government Pension Fund0.33%
Sovereign Wealth Fund0.28%
Insurance Company0.15%
Top holders as of 2026-06-30
FMR
12.75% · 4.89M sh
Access Industries, Inc.
7.33% · 2.81M sh
BlackRock
6.43% · 2.47M sh
RA Capital Management, L.P.
6.38% · 2.45M sh
T. Rowe Price Group, Inc.
4.88% · 1.88M sh
J.P. Morgan Asset Management, Inc.
4.78% · 1.84M sh
Wellington Management Group
4.54% · 1.74M sh
State Street Global Advisors
4.29% · 1.65M sh
Vanguard Capital Management, LLC
4.15% · 1.59M sh
Vestal Point Capital, LP
4.04% · 1.55M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 22 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| John Quisel | CEO, President, Secretary & Director | 0.30% |
| William Savage | Chief Medical Officer | 0.09% |
| Pamela Stephenson | Chief Commercial Officer | 0.05% |
| Rahul Khara | General Counsel, Compliance Officer & Secretary | 0.05% |
| Donald Nicholson | Independent Executive Chairman | 0.04% |
| Jonathan Yu | Chief Business Officer | 0.03% |
| Joanne Bryce | Chief Financial Officer | 0.02% |
| Atlas Venture Advisors, Inc. | -- | -- |
| OrbiMed Advisors LLC | -- | -- |
| Access Industries, Inc. | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | John Quisel | CEO, President, Secretary & Director | Derivative Exercise and Retained | +36,000 | $1.01 |
| 2026-09-10 | Kevin Bitterman | Independent Director | Derivative Exercise and Sale | -27,136 | $38.85–70.11 |
| 2026-09-03 | Atlas Venture Advisors, Inc. | -- | Automatic Disposition | -1,689 | $79.96 |
| 2026-09-02 | Atlas Venture Advisors, Inc. | -- | Automatic Disposition | -54,496 | $79.95–80.98 |
| 2026-08-24 | Jonathan Yu | Chief Business Officer | Derivative Exercise and Sale | -9,096 | $13.50–83.12 |
| 2026-08-16 | John Quisel | CEO, President, Secretary & Director | Derivative Exercise and Sale | -33,000 | $13.50–79.84 |
| 2026-08-11 | Jonathan Yu | Chief Business Officer | Derivative Exercise and Sale | -804 | $13.50–82.64 |
| 2026-08-05 | Rahul Khara | General Counsel, Compliance Officer & Secretary | Derivative Exercise and Sale | -5,000 | $14.69–80.00 |
| 2026-07-12 | John Quisel | CEO, President, Secretary & Director | Derivative Exercise and Sale | -33,000 | $9.86–76.05 |
| 2026-07-06 | Jonathan Yu | Chief Business Officer | Derivative Exercise and Sale | -100 | $13.50–82.50 |
| 2026-06-28 | Rahul Khara | General Counsel, Compliance Officer & Secretary | Derivative Exercise and Sale | -2,500 | $14.69–75.00 |
| 2026-06-25 | Jonathan Yu | Chief Business Officer | Derivative Exercise and Sale | -300 | $13.50–72.50 |
| 2026-06-21 | Jonathan Yu | Chief Business Officer | Derivative Exercise and Sale | -9,700 | $13.50–72.66 |
| 2026-06-17 | Georges Gemayel | Director | Other Derivative Acquisition | +6,212 | $70.79 |
| 2026-06-17 | Kevin Bitterman | Independent Director | Other Derivative Acquisition | +6,212 | $70.79 |
| 2026-06-17 | Liam Ratcliffe | Independent Director | Other Derivative Acquisition | +6,212 | $70.79 |
| 2026-06-17 | John Quisel | CEO, President, Secretary & Director | Derivative Exercise and Sale | -34,000 | $9.86–71.61 |
| 2026-06-17 | Mark Chin | Independent Director | Other Derivative Acquisition | +6,212 | $70.79 |
| 2026-06-17 | Donald Nicholson | Independent Executive Chairman | Other Derivative Acquisition | +6,212 | $70.79 |
| 2026-06-17 | William White | Independent Director | Other Derivative Acquisition | +6,212 | $70.79 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:13:37 · For reference only, not investment advice and not tailored to your situation.